Trademarks for Pharmaceuticals in Nepal (DDA + DoI)

A pharmaceutical trademark in Nepal needs two separate approvals: DoI trademark registration under the Patent, Design and Trademark Act 1965 (PDTA), and DDA drug-name approval for the medicine. DoI registration commonly takes 12–14 months when unopposed, so plan the brand and product work together.

Key Takeaways

Pharmaceutical brand protection in Nepal depends on the Department of Industry (DoI) and the Department of Drug Administration (DDA), which assess different risks. The PDTA gives registered marks a seven-year renewable term, while the DDA assesses whether a medicine name is suitable for use on a regulated product.

• Class 5 is the starting NICE Classification class for medicines, pharmaceutical preparations, supplements and disinfectants.
• DoI trademark registration protects the brand as intellectual property; it does not itself authorise medicine sales.
• DDA drug-name approval is separate from DoI examination and can raise safety concerns about similar medicine names.
• Nepal is first-to-file, so the first valid application matters more than who used a brand first.
• One trademark application covers one NICE class only; pharmacy retail and laboratory services may need separate filings.
• The Industrial Property Bulletin publishes accepted marks, followed by a 90-day opposition period in practice.
• Foreign pharmaceutical owners need a direct Nepal filing through a Nepal-based representative because Nepal is outside the Madrid System.

Why do pharmaceutical trademarks need both DDA and DoI clearance?

The DoI decides trademark rights under the PDTA, while the DDA considers the proposed drug name in its medicine-regulatory process. A registered mark can therefore still be unsuitable for a pharmaceutical product name, and DDA acceptance does not replace the exclusive brand protection created through DoI registration.

A trademark identifies commercial source. It can be a wordmark, logo, symbol, or combination used to distinguish your goods or services. For medicines, the public-health concern is sharper: confusing names can contribute to dispensing or prescribing mistakes. The DDA and DoI therefore have different jobs, even where they consider the same proposed brand.

Do not treat one clearance as proof of the other. Before printing cartons, labels, promotional literature, or launching a product dossier, test the name from both angles. In practice, a pharmaceutical company should keep its regulatory and IP teams working from the same approved spelling, presentation, and product list.

Which NICE classes apply to pharmaceutical trademarks in Nepal?

Class 5 covers pharmaceutical and veterinary preparations, sanitary preparations, dietary supplements, and disinfectants under the NICE Classification, which has 45 classes. Sec. 18A requires a separate DoI application for each class, so a medicine brand may need Class 5 plus further protection for distinct commercial activities.

Class selection follows what you actually offer, not what you may offer one day. NICE classes 1–34 cover goods, while Classes 35–45 cover services. A strong pharmaceutical filing normally begins with a precise Class 5 goods description, then adds other classes only where there is a genuine present or planned use.

When should a pharmaceutical business add Class 3, 35, or 42?

Class 3 may suit non-medicated skin-care products or toiletries sold under the same house mark. Class 35 can matter for a pharmacy chain’s retail identity. Class 42 may fit laboratory, testing, or scientific research services. These classes do not automatically follow Class 5; each needs its own application and DoI examination.

How do you register a pharmaceutical trademark with the DoI?

The DoI registration process starts with a clearance review and ends with a certificate after examination, Industrial Property Bulletin publication, and a 90-day opposition window. Under Sec. 17–18 and Sec. 21A of the PDTA, the applicant must file separately for every relevant NICE class and respond if concerns arise.

1. Clear the proposed name and logo. Search identical and close marks in Class 5 and any related classes. Start with the public Nepal trademark database search, then consider a professional similarity review for difficult names, phonetic variants, and logo conflicts.
2. Set the goods and classes. Identify the medicine, supplement, disinfectant, or service you will protect. The NICE class finder can help you separate Class 5 goods from retail or scientific services.
3. Prepare the application record. Confirm the owner’s legal name, address, mark representation, and product description. Make sure the proposed DoI mark matches the brand spelling being considered for the DDA process.
4. File with the Department of Industry. DoI records the application in the selected class. Nepal is first-to-file, so avoid waiting until the product is near launch to secure a filing date.
5. Answer examination issues. The DoI checks whether the mark conflicts with an earlier mark, damages another mark’s goodwill, or falls within a refusal ground under Sec. 18.
6. Watch publication and opposition. Accepted applications are published in the Industrial Property Bulletin. A third party can oppose during the 90-day practice window, and DoI may conduct an inquiry before deciding the matter.
7. Obtain the certificate and maintain it. Once registration completes, retain the registration certificate and renew the mark every seven years. Keep use records as well, because Sec. 18C addresses non-use after registration.

The DDA track should run with the product licensing work, not as an afterthought. Your regulatory adviser should confirm the drug-name requirements, formulation records, label requirements, and product documentation applicable to the medicine. This article is general information, not legal or regulatory advice; ask our team for help through pharmaceutical trademark and filing advice.

Which documents support a pharmaceutical trademark application?

A domestic DoI application commonly needs the application form, trademark label, notarised power of attorney, board resolution, industry certificate, and current tax-clearance evidence. Foreign applicants also need home-registration evidence where applicable. The PDTA filing process is separate from the DDA’s product-specific records and regulatory documents.

• Clear image specimens of the proposed wordmark, logo, or combined label.
• Applicant identity details that match the company or individual owner.
• A notarised power of attorney where a representative files for you.
• Company authority documents, including a board resolution where the owner is a company.
• Priority filing evidence in English if you claim Paris Convention priority.
• For foreign owners, certified or notarised home trademark registration material in English where required.

A common mistake we see is putting a distributor, manufacturer, or local importer down as owner without checking the commercial arrangement. The registered owner controls the mark. Resolve ownership before filing, especially where a foreign parent, Nepali importer, and contract manufacturer all appear on packaging.

How long do DoI registration and DDA approval take?

DoI trademark registration usually takes about 12–14 months from filing to certificate when unopposed, although the smoothest straightforward matters can finish in about 6–8 months. DDA drug-name approval follows its own review path, so no single combined timeline should be assumed for every pharmaceutical product.

What affects the cost of a pharmaceutical trademark filing?

The total cost depends on the number of NICE classes, whether the mark is a wordmark or logo, document preparation, foreign-owner formalities, examination responses, and any opposition. DoI charges and professional work are separate, so use the current trademark fee calculator or request a current estimate before filing.

Class 5 is not a blanket filing for an entire pharmaceutical group. A company that protects a medicine name, a pharmacy-store identity, and a non-medicated cosmetics range may need several applications. That per-class structure is often the main planning point, before considering clearance work or a contested opposition.

What Nepal IP law governs pharmaceutical brand protection?

The Patent, Design and Trademark Act 1965 governs DoI trademark registration in Nepal, including ownership through registration under Sec. 16, filing under Sec. 17, refusal grounds in Sec. 18, and class-specific applications under Sec. 18A. The official Nepal Law Commission publishes legal materials, while the DoI administers the system.

Sec. 18 prevents registration of marks already registered in another person’s name and marks that damage another mark’s goodwill. For pharmaceutical names, this means you should test visual, spoken, and overall similarity. Adding a short prefix, changing one letter, or using a different colour may not cure a close conflict.

Nepal belongs to the Paris Convention and TRIPS framework, but it is not in the Madrid System. A foreign pharmaceutical company cannot extend an international registration automatically into Nepal. It should file directly through a Nepal-based agent, and may consider a Paris Convention priority claim where the facts support it. WIPO’s treaty resources provide useful background on those international frameworks.

Which mistakes can delay a pharmaceutical trademark in Nepal?

The most costly pharmaceutical trademark mistakes arise before DoI filing: choosing a name too close to an earlier Class 5 mark, treating DDA review as an IP search, or filing under the wrong owner. Because Nepal is first-to-file, a late applicant can lose the practical advantage even after investing heavily in labels and regulatory preparation.

How would a Nepali medicine company protect a new brand name?

Imagine a Kathmandu manufacturer planning to sell a fever-relief tablet under the proposed name “SwasthaCare.” It should search Class 5 and related records first, file the chosen wordmark with the DoI, and submit the same proposed name through the relevant DDA drug-name process before committing to cartons or distributor material.

If the search finds “Swastha Cure” for similar pharmaceutical preparations, the company should not assume the extra word solves the problem. It should assess the similarity before filing, then consider a more distinctive replacement. Distinctive coined names are usually easier to defend than names built mainly from health, cure, pharma, or medicine language.

If the company also plans branded pharmacy outlets called “SwasthaCare Pharmacy,” it should assess Class 35. If it offers laboratory testing under the same name, it should consider Class 42. The brand owner should keep each filing record, DDA correspondence, product labels, and eventual registration certificate together for later enforcement and renewal.

What are the alternatives and edge cases for medicine brands?

A pharmaceutical trade mark does not protect a drug formula, packaging shape, or company name by itself. The DoI can register a wordmark, logo, or combined mark under the PDTA, while patents and industrial designs protect different subject matter. The Office of the Company Registrar (OCR) company-name record is also not a substitute for DoI trademark registration.

A logo may deserve a separate filing where it will be used independently from the medicine name. A registered wordmark is often broader for stopping name use, while a logo filing protects the actual visual device shown in the application. If packaging has a genuinely original appearance, discuss industrial-design protection separately rather than assuming a trademark covers the shape.

Where a competitor’s mark appears in the Industrial Property Bulletin, opposition must be considered quickly. Where copying starts after your registration, enforcement may be needed. Our team can help assess the record and options through the appropriate trademark service; do not rely on this guide alone for a dispute decision.

In short, what should pharmaceutical companies do first?

Pharmaceutical companies should clear a distinctive Class 5 name, file early with the DoI, and coordinate the separate DDA drug-name approval work before launch. The DoI certificate gives renewable trademark rights for seven-year periods; the DDA process addresses whether the name can be used for the regulated medicine.

• Search before naming the product or printing labels.
• File the wordmark in Class 5 as early as possible.
• Add other NICE classes only where your business needs them.
• Keep DDA and DoI workstreams aligned on the exact brand name.
• Renew the registered mark and retain evidence of real use.

People also search for

These related Nepal trademark guides explain the wider DoI process, class selection, clearance work, foreign filings, and common refusal issues. They are useful if your pharmaceutical business is still choosing a name, preparing documents, or deciding how to protect a logo alongside the medicine brand.

• How to register a trademark in Nepal
• What is NICE Classification for trademarks?
• How to choose the right trademark class in Nepal
• How to search for a trademark in Nepal
• What counts as a confusingly similar trademark in Nepal?
• Documents required for trademark registration in Nepal
• How foreign companies register a trademark in Nepal

Before you commit to a pharmaceutical brand, search existing Nepal trademarks, review the trademark registration service, and contact our team for help with Class 5 filing, DDA coordination, and DoI trademark registration.